

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 23.06A of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities of The GEM (“**GEM**”) of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) hereby announces that on 28 December 2022, the Company granted share options (the “**Option(s)**”) to certain eligible persons (the “**Grantees(s)**”), being the Directors and certain employees of the Company and its subsidiaries pursuant to the share option scheme of the Company adopted on 9 June 2021 (the “**Scheme**”) to subscribe for a total of 263,900,000 new ordinary shares with nominal value of HK\$0.0125 each in the share capital of the Company (the “**Share(s)**”), subject to acceptance of the Grantees. Details of such grant are as follows:

Date of grant:	28 December 2022
Exercise price of the Options granted:	HK\$0.04 per Share
Closing price of the Shares on the date of grant of the Options:	HK\$0.035 per Share
Average closing price per Share as stated in the daily quotation sheets of the Stock Exchange for the five trading days immediately preceding the date of grant:	HK\$0.0396 per Share
Nominal value of the Share:	HK\$0.0125 per Share

Number of Options granted: 263,900,000 Options, each Option shall entitle the Grantees to subscribe for one Share

Validity period of the Options: From the date of grant up to 30 June 2028 (both days inclusive) and the Options granted are exercisable in stages from 1 July 2023 to 30 June 2028 (both days inclusive), subject to the provisions for each termination contained in the Scheme and certain vesting conditions applicable to the relevant Grantee(s).

Among the Options granted, a total of 131,000,000 Options were granted to seven employees of the Company and the remaining 132,900,000 Options were granted to the following Directors:

<u>Name</u>	<u>Position</u>	<u>No. of the Options granted</u>
Mr. CHAU Wai Wah Fred	Executive Director	40,000,000
Mr. HO Kam Kin	Executive Director	40,000,000
Ms. KWOK Shuk Yi	Executive Director	40,000,000
Dr. CHENG Yanjie	Non-executive Director	4,000,000
Mr. LAU Fai Lawrence	Independent Non-executive Director	4,000,000
Dr. LIU Ta-pei	Independent Non-executive Director	900,000
Mr. LAM Kit Sun	Independent Non-executive Director	4,000,000
		<u>132,900,000</u>
		=====

Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or any of their respective associate(s) (as defined in the GEM Listing Rules). The grant of the Options to the above Directors has been approved by the independent non-executive Directors of the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 28 December 2022

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, and Dr. CHENG Yanjie as non-executive Director, and LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. LAM Kit Sun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.